Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to shrink prostate tumors before surgery

NCT ID NCT05498272

First seen Jan 24, 2026 · Last updated Jun 18, 2026 · Updated 26 times

Summary

This study tests whether taking a targeted drug (olaparib) plus hormone therapy for 6 months before prostate removal surgery can eliminate or shrink tumors in men with high-risk prostate cancer. Participants must have specific gene changes (HRR alterations). The goal is to see if this approach leads to no cancer or only tiny spots of cancer left at surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact Email: •••••@•••••

    Contact

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Penn Medicine Abramson Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Email: •••••@•••••

    Contact

  • University of California San Diego - Moores Cancer Center

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Email: •••••@•••••

    Contact

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.